Role of IGF-I in follistatin-induced skeletal muscle hypertrophy

A Soluble Activin Receptor Type IIB Does Not Improve Blood Glucose in Streptozotocin-Treated Mice

(2015) Qian Wang et al.   International Journal of Biological Sciences

Local overexpression of the myostatin propeptide increases glucose transporter expression and enhances skeletal muscle glucose disposal

(2014) M. E. Cleasby et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

REDD1 enhances protein phosphatase 2A-mediated dephosphorylation of Akt to repress mTORC1 signaling

(2014) M. D. Dennis et al.   Science Signaling

Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice

(2013) Juha J. Hulmi et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass

(2013) Catherine E. Winbanks et al.   JOURNAL OF CELL BIOLOGY

An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy

(2013) E. Lach-Trifilieff et al.   MOLECULAR AND CELLULAR BIOLOGY

A PGC-1α Isoform Induced by Resistance Training Regulates Skeletal Muscle Hypertrophy

(2012) Jorge L. Ruas et al.   CELL

Combined Effect of AAV-U7-Induced Dystrophin Exon Skipping and Soluble Activin Type IIB Receptor in mdx Mice

(2012) Willem M.H. Hoogaars et al.   HUMAN GENE THERAPY

Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin

(2012) Catherine E. Winbanks et al.   JOURNAL OF CELL BIOLOGY

Altered REDD1, myostatin, and Akt/mTOR/FoxO/MAPK signaling in streptozotocin-induced diabetic muscle atrophy

(2011) Juha J. Hulmi et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway

(2011) C. Zhang et al.   DIABETOLOGIA

The Type 1 Insulin-Like Growth Factor Receptor (IGF-IR) Pathway Is Mandatory for the Follistatin-Induced Skeletal Muscle Hypertrophy

(2011) S. Kalista et al.   ENDOCRINOLOGY

Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation

(2010) Elaine D. O’Neill et al.   AGE

Downregulation of Akt/mammalian target of rapamycin pathway in skeletal muscle is associated with increased REDD1 expression in response to chronic hypoxia

(2010) François B. Favier et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

The Role of GH and IGF-I in Mediating Anabolic Effects of Testosterone on Androgen-Responsive Muscle

(2010) Carlo Serra et al.   ENDOCRINOLOGY

Endocrine Actions of Myostatin: Systemic Regulation of the IGF and IGF Binding Protein Axis

(2010) Nolann G. Williams et al.   ENDOCRINOLOGY

Mechanisms involved in the enhancement of mammalian target of rapamycin signalling and hypertrophy in skeletal muscle of myostatin-deficient mice

(2010) Christopher Lipina et al.   FEBS LETTERS

Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type

(2010) Samuel M. Cadena et al.   JOURNAL OF APPLIED PHYSIOLOGY

Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice

(2010) Mahendra D. Mavalli et al.   JOURNAL OF CLINICAL INVESTIGATION

The Translation Regulatory Subunit eIF3f Controls the Kinase-Dependent mTOR Signaling Required for Muscle Differentiation and Hypertrophy in Mouse

(2010) Alfredo Csibi et al.   PLoS One

Akt Deficiency Attenuates Muscle Size and Function but Not the Response to ActRIIB Inhibition

(2010) Marcus D. Goncalves et al.   PLoS One

Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt

(2009) Michael R. Morissette et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin

(2009) Hélène Gilson et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

IGF-independent effects of insulin-like growth factor binding protein-5 (Igfbp5) in vivo

(2009) Gyanendra Tripathi et al.   FASEB JOURNAL

Myostatin Inhibition in Muscle, but Not Adipose Tissue, Decreases Fat Mass and Improves Insulin Sensitivity

(2009) Tingqing Guo et al.   PLoS One

The initiation factor eIF3-f is a major target for Atrogin1/MAFbx function in skeletal muscle atrophy

(2008) Julie Lagirand-Cantaloube et al.   EMBO JOURNAL

Role of Akt/GSK-3β/β-Catenin Transduction Pathway in the Muscle Anti-Atrophy Action of Insulin-Like Growth Factor-I in Glucocorticoid-Treated Rats

(2008) O. Schakman et al.   ENDOCRINOLOGY

Cellular and molecular regulation of muscle growth and development in meat animals1,2

(2008) W. R. Dayton et al.   JOURNAL OF ANIMAL SCIENCE

MAFbx/Atrogin-1 Controls the Activity of the Initiation Factor eIF3-f in Skeletal Muscle Atrophy by Targeting Multiple C-terminal Lysines

(2008) Alfredo Csibi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Insulin-Like Growth Factor-Binding Protein-5 Inhibits Osteoblast Differentiation and Skeletal Growth by Blocking Insulin-Like Growth Factor Actions

(2008) Aditi Mukherjee et al.   MOLECULAR ENDOCRINOLOGY

Proteomic Identification and Functional Validation of Activins and Bone Morphogenetic Protein 11 as Candidate Novel Muscle Mass Regulators

(2008) Tatyana A. Souza et al.   MOLECULAR ENDOCRINOLOGY